DOCSLIB.ORG

Biotech in Europe Investor Forum

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

WELCOME PHARMA LICENSING GROUPS 12th Annual BIOTECH IN EUROPE SPEAKERS INVESTOR FORUM 1st-2nd October 2012 PRESENTING COMPANIES Hilton Zurich Airport Hotel, Switzerland Conference Guide SUPPORTING ORGANISATIONS SUPPORTING ORGANISERS www.sachsforum.com BIOTECH IN EUROPE INVESTOR FORUM WELCOME next u Welcome PHARMA LICENSING Sachs Associates are delighted to welcome you to the: 12th Annual Biotech in Europe GROUPS Investor Forum 1st-2nd October 2012 Hilton Zurich Airport Hotel, Switzerland Sachs Associates are delighted to welcome you to the 12th Annual Biotech in Europe Investor SPEAKERS Forum. Following the success of previous years, the forum once again provides access to an exciting cross-section of venture-funded and small-cap companies with leading investors and pharmas. This Forum is highly transactional and is comprised of a series of panels and presentations from leading investment, pharmaceutical and biotech companies, each one providing an expert outlook on growth and investment activity in Europe’s Biotech industry. The programme highlights the current issues surrounding the evolving M&A market, the Private PRESENTING COMPANIES Equity & Venture Capital environment and a special session on major trends in Partnering. Plus, this year’s programme features more than 70 company presentations from a range of publicly listed and private life science companies looking to raise finance and/or find partners. General Information The registration desk will be open from 8am on October 1st and from 8.15am on October 2nd although you are welcome to join the event at any time. Please collect a copy of the agenda for information on timing and room allocation for each session. Networking at the Forum is facilitated by our online 1-2-1 meeting system, which is available to all participants. ORGANISATIONS SUPPORTING A Networking Lunch will be set up in the Zurich A & B rooms. Coffee stations will be set up in the Zurich A & B rooms and the presentation rooms throughout the event. Request for Presentations Please use the agenda to mark off presentations that you are interested in and email your request to [email protected] after the conference. We will endeavour to send you the requested presentations as soon as we have been granted permission to do so by that specific presenter. Please note that we DO NOT have copies of the slides that are shown during the conference. ORGANISERS t WELCOME back Events Diary PHARMA LICENSING For regular updates, sponsorship, presenting and attending opportunities and further information regarding any of our future events please contact Zoe Harris on [email protected] 6th Annual GROUPS European Life Science CEO Forum For Partnering & Investing 5th – 6th March 2013 • Zurich • Switzerland Back for its sixth year, this exclusive and highly transactional partnering event is a must for companies wishing to meet with their peers, engage with leading investors and forge new SPEAKERS partnerships. Building on the success of this year’s event, the forum will provide an excellent platform to gain insight into partnering and investment trends in the Biotech and Pharma industry. Networking at the Forum is facilitated by our online 1-2-1 meeting system, which is available to all participants. The conference will feature up to 8 presentations by large to mid size pharmaceutical companies looking for strategic alliances/partners. PRESENTING COMPANIES Do not miss out on this great opportunity to meet emerging companies, leading global investors and Big Pharma representatives! Annual Cancer Bio Partnering Forum Promoting Public & Private Sector, Collaboration & Investment in Drug Development 21st – 22nd May 2013 • Boston • USA SUPPORTING ORGANISATIONS SUPPORTING 13th Annual Biotech in Europe Investor Forum 30th September – 1st October 2013 • Zurich • Switzerland ORGANISERS WELCOME Pharma Licensing Groups PHARMA LICENSING Pharma www.amgen.co.uk Licensing Groups www.astellas.eu represented at the GROUPS www.biogenidec.co.uk Forum www.helsinn.com www.ipsen.com SPEAKERS www.jnj.com www.menarini-biotech.com PRESENTING COMPANIES www.merck.com www.merckserono.co.uk/en/index.html www.norgine.com www.novartisoncology.com SUPPORTING ORGANISATIONS SUPPORTING www.novartisvaccines.com www.pierre-fabre.com www.roche.com www.sanofi.com ORGANISERS www.nycomed.com WELCOME Speakers PHARMA LICENSING Alexey Eliseev, Managing Director, Maxwell Biotech Alexey received his PhD in Chemistry from Moscow State University and MBA from the Sloan School of Management at the Massachusetts Institute of Technology. His career includes over 17 years of experience in academia, biotechnology industry and venture capital. Dr. Eliseev has been working in the United States and Europe since 1992. Following three years of postdoctoral research in Germany as an Alexander von Humboldt Fellow and in the US, he joined faculty at the department of Medicinal Chemistry, GROUPS University at Buffalo in 1995 where he was awarded tenure in 2000. In 1999 he co-founded the company Therascope (later Alantos Pharmaceuticals) with a number of prominent founders including French Nobel Laureate Jean-Marie Lehn. The company used a novel drug discovery technology developed in several academic labs, including Eliseev’s group in Buffalo. He joined the company in 2000 and later became Chief Technology Officer of Alantos and President of its US division. Alantos was acquired by Amgen in 2007 for $300 million. Over the recent years Alexey was involved in starting several biotech companies as a scientist and entrepreneur, including AC Immune (Switzerland) and Boston BioCom (US). Alexey has been working with the Russian-based Maxwell Biotech Venture Fund as its Managing Director since 2009. He is responsible for international activity of the Fund and has managed numerous t back :: deals with portfolio companies in the US and Europe. SPEAKERS next Allan Marchington, Partner, Apposite Capital u Allan is a founder and Partner at Apposite Capital a London based healthcare investor. Allan was formerly at Abingworth management and prior to this was a member of Millennium Pharmaceuticals management team as an Senior Vice President with responsibility for technology Investments. He also served as Chairman of Millennium Pharmaceuticals in Europe. Allan joined Millennium following their acquisition in July 2000 of Cambridge Discovery Chemistry, where he was CEO and founder. Allan began his career as a medicinal chemist at Pfizer Central Research. PRESENTING COMPANIES Allan is a Board member of the BioIndustry Association, Ambit Biosciences Inc., Ambrx Inc., Anaphore Inc., and Convergence Pharmaceuticals Ltd. Dr Andreas Caduff, CEO, BioVoition AG Andreas was born in 1971 and is a Swiss citizen. He held various positions in the pharmaceutical and medical device industry. In his previous position he was serving as CTO of Solianis Monitoring AG, a company focusing on noninvasive glucose monitoring. At Solianis, he orchestrated the overall technology and product development, experimental/clinical study strategies, regulatory considerations, external technical communication and interaction with the industrial/scientific community, regulatory bodies as well as the investor’s community. He is an expert in physiological monitoring techniques and involved physiological/metabolic processes, combining the expertise in various fields relevant to the development, industrialisation and commercialisation of such technologies. Dr. Caduff is a frequent invited speaker at industrial and scientific conferences and meetings on physiological monitoring, mobile Health and related subjects. He has innovated numerous patents and co-authored several dozen scientific publications in peer reviewed journals. He holds a BSc degree ORGANISATIONS SUPPORTING in Chemistry from the University of Applied Science, Winterthur, Switzerland, an MSc degree in Biotechnology and a Ph.D. in Biophysics from the University of Teesside, UK and the Hebrew University of Jerusalem, Israel. Anne Altmeyer, Executive Director Business Development & Licensing, Novartis Oncology Anne is a Vice President in Business Development and Licensing in the Oncology Business Unit at Novartis, USA. Her responsibilities are to in-license or acquire Oncology assets that can further strengthen the Novartis Oncology portfolio. In this role, she identifies, evaluates, and negotiates transactions for oncology opportunities. She also manages several ongoing alliances. Anne has over 15 years of experience in the Pharmaceutical Industry working in positions of increasing responsibilities in Research, Development, and Business Development and Licensing. Anne joined the Oncology Project Management group of Novartis in 2004 as a Project Leader. There she led numerous multidisciplinary Project Teams through the generation and implementation of strategies for various compounds in development and on the market. Before joining Novartis, Anne worked as a Project Manager at Merck & Co. for close to 4 years and as a Visiting Research Scientist for 2 years. Anne received her Ph.D. in Molecular Immunology from Strasbourg University, France. She then performed a postdoctoral ORGANISERS fellowship at New York University School of Medicine, USA, and subsequently became a Research Associate at Cornell University Medical College, New York, USA. In addition to her scientific training, Anne also received a Master in Business Administration and a Master in Public Health from the University of Medicine and Dentistry of New Jersey/Rutgers, USA. WELCOME Speakers PHARMA LICENSING Arthur
Recommended publications
  • The Promise of Human Genome Editing for Rare and Genetic Disease Summary Report of the 2019 FORUM Annual Lecture

    The Promise of Human Genome Editing for Rare and Genetic Disease Summary Report of the 2019 FORUM Annual Lecture

    The promise of human genome editing for rare and genetic disease Summary report of the 2019 FORUM Annual Lecture The Academy of Medical Sciences The Academy of Medical Sciences is the independent body in the UK representing the diversity of medical science. Our mission is to promote medical science and its translation into benefits for society. The Academy’s elected Fellows are the United Kingdom’s leading medical scientists from hospitals, academia, industry and the public service. We work with them to promote excellence, influence policy to improve health and wealth, nurture the next generation of medical researchers, link academia, industry and the NHS, seize international opportunities and encourage dialogue about the medical sciences. Opinions expressed in this report do not necessarily represent the views of all participants at the event, the Academy of Medical Sciences, or its Fellows. All web references were accessed in February 2020. This work is © Academy of Medical Sciences and is licensed under Creative Commons Attribution 4.0 International. The Academy of Medical Sciences 3 The promise of human genome editing for rare and genetic disease Summary report of the 2019 FORUM Annual Lecture Contents Executive summary .................................................................................................... 4 An introduction to genome editing ................................................................................ 6 Genome editing: moving to the clinic ...........................................................................
  • Development of Swiss Biotechnology Beyond the Biopharmaceutical Sector in Memoriam Prof

    Development of Swiss Biotechnology Beyond the Biopharmaceutical Sector in Memoriam Prof

    BUILDING BRIDGES BETWEEN BIOTECHNOLOGY AND CHEMISTRY – IN MEMORIAM ORESTE GHISALBA CHIMIA 2020, 74, No. 5 345 doi:10.2533/chimia.2020.345 Chimia 74 (2020) 345–359 © H.P. Meyer and O. Werbitzky Development of Swiss Biotechnology Beyond the Biopharmaceutical Sector In memoriam Prof. Dr. Oreste Ghisalba (1946–2018) Hans-Peter Meyera* and Oleg Werbitzkyb Abstract: Although diverse, the potential business opportunities for biotechnology outside the biopharmaceutical market are very large. White biotechnology can offer sustainable operations and products, while investments tend to be lower than those in red biotechnology. But a number of bottlenecks and roadblocks in Switzerland must be removed to realise the full potential of white biotechnology. This was also the point of view of Oreste Ghisalba, who wanted to be part of a new initiative to facilitate the creation of additional business, new pro- cesses and new products. This initiative requires the identification and the use of synergies and a much better cooperation between academia and industry through targeted networking. Unfortunately, we must carry on with this task without Oreste, whom we will miss for his deep knowledge and friendship. Keywords: Bio-based · Fine chemicals · Industrial biotechnology · Swiss economy · White biotechnology Hans-Peter Meyer holds a PhD in micro- venture partners and Managing Director of NC Health Sciences biology from the University of Fribourg since 2015. (Switzerland). He spent three years post- graduate and postdoc studies at the STFI 1. A Short History of the Swiss Biotechnology Industry in Stockholm (Sweden), the University The Swiss pharmaceutical and chemical industries have been of Pennsylvania and Lehigh University in responsible for almost half of the country’s exports for many years the USA.
  • A CB1 Receptor Antagonist As a Direct Interactional Partner for Μ- and Δ-Opioid Receptor

    A CB1 Receptor Antagonist As a Direct Interactional Partner for Μ- and Δ-Opioid Receptor

    Rimonabant: a CB1 receptor antagonist as a direct interactional partner for μ- and δ-opioid receptor Ph.D. thesis Ferenc Zádor Supervisor: Dr. Sándor Benyhe Institute of Biochemistry Biological Research Center of the Hungarian Academy of Sciences Szeged, Hungary 2014 TABLE OF CONTENTS LIST OF PUBLICATIONS ...................................................................................................... i LIST OF ABBREVIATIONS .................................................................................................. ii 1 REVIEW OF THE LITERATURE ................................................................................. 1 1.1 G-protein coupled receptors (GPCR) .............................................................................. 1 1.1.1 About GPCRs in general ................................................................................................................ 1 1.1.2 The structure of GPCRs ................................................................................................................. 3 1.1.3 The spectrum of GPCR ligand efficacy and constitutive activity of GPCRs ................................. 3 1.1.4 GPCR signaling: the G-protein activation/deactivation cycle ....................................................... 4 1.1.5 The complexity of GPCR signaling ............................................................................................... 6 1.2 Opioids and cannabinoids and their endogenous systems ............................................. 7 1.2.1 Opium poppy and the
  • History of Paediatric Treatment in the Reichsuniversität Straßburg (1941-1944) Aisling Shalvey

    History of Paediatric Treatment in the Reichsuniversität Straßburg (1941-1944) Aisling Shalvey

    History of paediatric treatment in the Reichsuniversität Straßburg (1941-1944) Aisling Shalvey To cite this version: Aisling Shalvey. History of paediatric treatment in the Reichsuniversität Straßburg (1941-1944). His- tory. Université de Strasbourg, 2021. English. NNT : 2021STRAG002. tel-03283700 HAL Id: tel-03283700 https://tel.archives-ouvertes.fr/tel-03283700 Submitted on 12 Jul 2021 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. UNIVERSITÉ DE STRASBOURG ÉCOLE DOCTORALE 519 Sciences humaines et sociales – Perspectives européennes [ ARCHE ] THÈSE présentée par : Aisling SHALVEY soutenue le : 12 mars 2021 pour obtenir le grade de : Docteur de l’université de Strasbourg Discipline/ Spécialité : Histoire Contemporaine de la Médecine History of Paediatric Treatment in the Reichsuniversität Straßburg (1941-1944) THÈSE dirigée par : Professeur MAURER Catherine Directrice du thèse, Université de Strasbourg Professeur WEINDLING Paul Directeur du thèse, Oxford Brookes University RAPPORTEURS : Professeur VON BUELTZINGSLOEWEN Isabelle Professor, Université Lumière Lyon 2 Professeur ROELCKE Volker Professor, Justus-Liebig- Universität Gießen AUTRES MEMBRES DU JURY : Professeur BONAH Christian Professor, Université de Strasbourg 1 Do mo sheantuismitheoirí Le grá 2 Acknowledgements I am extraordinarily lucky to have so many people who have supported me throughout the process of writing my PhD thesis; too many people to list, so I will begin by saying thank you to everyone who has helped me along the way.
  • PULSE: Speaker Biographies March 2019

    PULSE: Speaker Biographies March 2019

    PULSE: Speaker Biographies March 2019 Supported by @BIA_UK www.bioindustry.org In order of appearance: Dr Barbara Domayne-Hayman Entrepreneur-in-residence, Francis Crick Institute, CBO, Autifony Therapeutics Ltd and formerly Chairman, Puridify Barbara has worked on the commercial side of life sciences for thirty years, first in a large organisation (ICI/Zeneca/AstraZeneca), before transitioning to the entrepreneurial world of biotech. Barbara joined the Francis Crick Institute in January 2018 as Entrepreneur-in- residence. She is also Chief Business officer of Autifony, where she is responsible for strategic partnering, fundraising and commercial aspects of drug development for CNS disorders. In December 2017 Autifony signed a major collaboration with Boehringer Ingelheim. Barbara was also Chair of Puridify, a UCL spin-out with a breakthrough biotherapeutics purification technology, which was acquired by GE in November 2017. She chairs the LifeArc Seed Fund investment committee, and is on the Cambridge Enterprise Seed Fund Investment Committee. Previously, Barbara was CEO of Stabilitech, and she was Commercial Director at Arrow Therapeutics until the company was acquired by AstraZeneca. Barbara was also Senior Business Development Manager at Celltech. Barbara has a BA and D Phil in Chemistry from the University of Oxford, and is a Sloan Fellow from London Business School. Steve Bates, OBE CEO, BioIndustry Association Since his appointment as Chief Executive of the BioIndustry Association in 2012, Steve has led major BIA campaigns for, amongst other things, improved access to finance, the refilling of the Biomedical Catalyst, anti-microbial resistance and the opportunity the sector presents to generalist long term investors. Steve champions the adaptive pathway approach to the licensing of new drugs, the need for Early Access and is particularly proud of the working relationship the BIA has established with the UK’s leading medical research charities.
  • BBSRC Annual Report and Accounts 2007-08 HC

    BBSRC Annual Report and Accounts 2007-08 HC

    ANNUAL REPORT & ACCOUNTS 2007-2008 Biotechnology and Biological Sciences Research Council ANNUAL REPORT & ACCOUNTS 2007-2008 Presented to Parliament by the Secretary of State, and by the Comptroller and Auditor General, in pursuance of Schedule 1, Sections 2 [2] and 3 [3] of the Science and Technology Act 1965. Ordered to be printed by the House of Commons 16 July 2008. HC761 LONDON: The Stationery Office £18.55 Contents PART 1: MANAGEMENT COMMENTARY Chairman’s statement 1 Chief Executive’s report 3 Supporting world class research 6 Key funding data 7 Embedding Systems Biology 11 Major collaborative and multidisciplinary programmes 12 Delivering economic and social benefits 14 Collaborative research with industry 14 Commercialising research outputs 17 Tackling major challenges 20 People, skills, training and knowledge flows 22 Embedding our science in society 26 Opinion gathering and public dialogue 26 Outreach and engagement 28 Engaging young people in science 29 Corporate information 30 2007-2008 Council 30 Boards, Panels and Committees 31 Organisational developments 36 Financial review 39 Remuneration report 42 PART 2: ANNUAL ACCOUNTS Financial statements for the year ended 31 March 2008 45 This Annual Report covers the period from 1 April 2007 to 31 March 2008. BBSRC ANNUAL REPORT & ACCOUNTS BBSRC ANNUAL The Biotechnology and Biological Sciences Research Council (BBSRC), established by Royal Charter in 1994, is the UK’s principal funder of basic and strategic research across the biosciences (www. bbsrc.ac.uk). It is funded primarily by the Science Budget, through the Department for Innovation, Universities and Skills (DIUS). Our mission is to support high-class science and research training, and to promote knowledge transfer in support of bio-based industries and public engagement in bioscience.
  • Winter for the Membership of the American Crystallographic Association, P.O

    Winter for the Membership of the American Crystallographic Association, P.O

    AMERICAN CRYSTALLOGRAPHIC ASSOCIATION NEWSLETTER Number 4 Winter 2004 ACA 2005 Transactions Symposium New Horizons in Structure Based Drug Discovery Table of Contents / President's Column Winter 2004 Table of Contents President's Column Presidentʼs Column ........................................................... 1-2 The fall ACA Council Guest Editoral: .................................................................2-3 meeting took place in early 2004 ACA Election Results ................................................ 4 November. At this time, News from Canada / Position Available .............................. 6 Council made a few deci- sions, based upon input ACA Committee Report / Web Watch ................................ 8 from the membership. First ACA 2004 Chicago .............................................9-29, 38-40 and foremost, many will Workshop Reports ...................................................... 9-12 be pleased to know that a Travel Award Winners / Commercial Exhibitors ...... 14-23 satisfactory venue for the McPherson Fankuchen Address ................................38-40 2006 summer meeting was News of Crystallographers ...........................................30-37 found. The meeting will be Awards: Janssen/Aminoff/Perutz ..............................30-33 held at the Sheraton Waikiki Obituaries: Blow/Alexander/McMurdie .................... 33-37 Hotel in Honolulu, July 22-27, 2005. Council is ACA Summer Schools / 2005 Etter Award ..................42-44 particularly appreciative of Database Update:
  • Astex Pharmaceuticals Announces the Appointment of President Harren Jhoti, Phd to the Bioindustry Association Board of Directors

    Astex Pharmaceuticals Announces the Appointment of President Harren Jhoti, Phd to the Bioindustry Association Board of Directors

    October 10, 2012 Astex Pharmaceuticals Announces the Appointment of President Harren Jhoti, PhD to the BioIndustry Association Board of Directors DUBLIN, Calif., Oct. 10, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, announced that Harren Jhoti, PhD, president and director of Astex Pharmaceuticals, was appointed to the BioIndustry Association (BIA) Board of Directors. About Harren Jhoti, PhD Dr. Harren Jhoti has served as Astex Pharmaceuticals president and member of the Board of Directors since the company's formation in July 2011. He co-founded Astex Therapeutics in 1999 and was chief scientific officer until November 2007 when he was appointed chief executive. Dr. Jhoti was awarded the Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery by the European Federation for Medicinal Chemistry in 2012 and was also named by the Royal Society of Chemistry as "Chemistry World Entrepreneur of the Year" for 2007. He has published widely including in leading journals such as Nature and Science and has also been featured in TIME magazine after being named by the World Economic Forum a Technology Pioneer in 2005. Dr. Jhoti served as a non-executive director of Iconix Inc. Before starting up Astex Therapeutics in 1999, he was head of Structural Biology and Bioinformatics at GlaxoWellcome in the United Kingdom (1991-1999). Prior to Glaxo, Dr. Jhoti was a post-doctoral scientist at Oxford University. He received a BSc (Hons) in Biochemistry in 1985 and a PhD in Protein Crystallography from the University of London in 1989.
  • Global Equity Fund Description Plan 3S DCP & JRA MICROSOFT CORP

    Global Equity Fund Description Plan 3S DCP & JRA MICROSOFT CORP

    Global Equity Fund June 30, 2020 Note: Numbers may not always add up due to rounding. % Invested For Each Plan Description Plan 3s DCP & JRA MICROSOFT CORP 2.5289% 2.5289% APPLE INC 2.4756% 2.4756% AMAZON COM INC 1.9411% 1.9411% FACEBOOK CLASS A INC 0.9048% 0.9048% ALPHABET INC CLASS A 0.7033% 0.7033% ALPHABET INC CLASS C 0.6978% 0.6978% ALIBABA GROUP HOLDING ADR REPRESEN 0.6724% 0.6724% JOHNSON & JOHNSON 0.6151% 0.6151% TENCENT HOLDINGS LTD 0.6124% 0.6124% BERKSHIRE HATHAWAY INC CLASS B 0.5765% 0.5765% NESTLE SA 0.5428% 0.5428% VISA INC CLASS A 0.5408% 0.5408% PROCTER & GAMBLE 0.4838% 0.4838% JPMORGAN CHASE & CO 0.4730% 0.4730% UNITEDHEALTH GROUP INC 0.4619% 0.4619% ISHARES RUSSELL 3000 ETF 0.4525% 0.4525% HOME DEPOT INC 0.4463% 0.4463% TAIWAN SEMICONDUCTOR MANUFACTURING 0.4337% 0.4337% MASTERCARD INC CLASS A 0.4325% 0.4325% INTEL CORPORATION CORP 0.4207% 0.4207% SHORT-TERM INVESTMENT FUND 0.4158% 0.4158% ROCHE HOLDING PAR AG 0.4017% 0.4017% VERIZON COMMUNICATIONS INC 0.3792% 0.3792% NVIDIA CORP 0.3721% 0.3721% AT&T INC 0.3583% 0.3583% SAMSUNG ELECTRONICS LTD 0.3483% 0.3483% ADOBE INC 0.3473% 0.3473% PAYPAL HOLDINGS INC 0.3395% 0.3395% WALT DISNEY 0.3342% 0.3342% CISCO SYSTEMS INC 0.3283% 0.3283% MERCK & CO INC 0.3242% 0.3242% NETFLIX INC 0.3213% 0.3213% EXXON MOBIL CORP 0.3138% 0.3138% NOVARTIS AG 0.3084% 0.3084% BANK OF AMERICA CORP 0.3046% 0.3046% PEPSICO INC 0.3036% 0.3036% PFIZER INC 0.3020% 0.3020% COMCAST CORP CLASS A 0.2929% 0.2929% COCA-COLA 0.2872% 0.2872% ABBVIE INC 0.2870% 0.2870% CHEVRON CORP 0.2767% 0.2767% WALMART INC 0.2767%
  • Guidelines with Regard to the Composition, Calculation and Management of the Index

    Guidelines with Regard to the Composition, Calculation and Management of the Index

    INDEX METHODOLOGY Solactive Pharma Breakthrough Value Index Version 2.1 dated September 03, 2020 Contents Important Information 1. Index specifications 1.1 Short Name and ISIN 1.2 Initial Value 1.3 Distribution 1.4 Prices and Calculation Frequency 1.5 Weighting 1.6 Index Committee 1.7 Publication 1.8 Historical Data 1.9 Licensing 2. Composition of the Index 2.1 Selection of the Index Components 2.2 Ordinary Adjustment 2.3 Extraordinary Adjustment 3. Calculation of the Index 3.1 Index Formula 3.2 Accuracy 3.3 Adjustments 3.4 Dividends and other Distributions 3.5 Corporate Actions 3.6 Correction Policy 3.7 Market Disruption 3.8 Consequences of an Extraordinary Event 4. Definitions 5. Appendix 5.1 Contact Details 5.2 Calculation of the Index – Change in Calculation Method 2 Important Information This document (“Index Methodology Document”) contains the underlying principles and regulations regarding the structure and the operating of the Solactive Pharma Breakthrough Value Index. Solactive AG shall make every effort to implement regulations. Solactive AG does not offer any explicit or tacit guarantee or assurance, neither pertaining to the results from the use of the Index nor the Index value at any certain point in time nor in any other respect. The Index is merely calculated and published by Solactive AG and it strives to the best of its ability to ensure the correctness of the calculation. There is no obligation for Solactive AG – irrespective of possible obligations to issuers – to advise third parties, including investors and/or financial intermediaries, of any errors in the Index.
  • Selection and Characterization of Amyloid-Β1-42 Binding D-Enantiomeric Peptides for Potential Therapeutic Intervention of Alzheimer´S Disease

    Selection and Characterization of Amyloid-Β1-42 Binding D-Enantiomeric Peptides for Potential Therapeutic Intervention of Alzheimer´S Disease

    Selection and characterization of Amyloid-β1-42 binding D-enantiomeric peptides for potential therapeutic intervention of Alzheimer´s disease Inaugural-Dissertation zur Erlangung des Doktorgrades der Mathematisch-Naturwissenschaftlichen Fakultät der Heinrich-Heine-Universität Düsseldorf vorgelegt von Stephan Rudolph aus Dessau Düsseldorf, April 2015 Die vorliegende Arbeit wurde in der Zeit von April 2011 bis Februar 2015 am Institut für Physikalische Biologie der Heinrich-Heine-Universität Düsseldorf unter der Leitung von Prof. Dr. Dieter Willbold angefertigt. Gedruckt mit der Genehmigung der Mathematisch-Naturwissenschaftlichen Fakultät der Heinrich-Heine-Universität Düsseldorf Referent: Prof. Dr. Dieter Willbold Koreferent: Prof. Dr. Georg Groth Tag der mündlichen Prüfung: „Die Dummheiten wechseln, und die Dummheit bleibt.“ (Erich Kästner) „Die dunkelste Stunde ist die vor Sonnenaufgang.“ (chinesisches Sprichwort) Für Tante Elli Index Index Index I - IV 1. Introduction 1 1.1 Alzheimer´s disease (AD) – an overview .................................................... 1 1.1.1 General information ............................................................................. 1 1.1.2 History and pathology of AD ................................................................ 3 1.1.3 The amyloid precursor protein (APP) ................................................... 4 1.1.4 From APP to Aβ ................................................................................... 7 1.1.5 The physiological role of Aβ and Tau .................................................
  • Sources 4 Web.Pdf

    Sources 4 Web.Pdf

    SOURCE(S) Cahiers de l’équipe de recherche Arts, Civilisation et Histoire de l’Europe N° 4 - premier semestre 2014 SOURCE(S) Cahiers de l’équipe de recherche Arts, Civilisation et Histoire de l’Europe Directeur de la publication : Nicolas Bourguinat Comité de rédaction : Laurence Buchholzer, Anne Corneloup, Jean-Pascal Gay Numéro coordonné par : Jean-Pascal Gay Secrétariat de rédaction : Laurence Buchholzer, Anne Corneloup, Simone Herry Assistant de rédaction : Guillaume Porte La revue SOURCE(S) est un organe de l’Équipe d’Accueil ARCHE-EA 3400 de l’Université de Strasbourg. Pour les informations sur la revue et les autres activités de l’équipe : www.ea3400.unistra.fr Adresse de la rédaction : Revue SOURCE(S) - Faculté des Sciences Historiques, équipe ARCHE, à l’att. de N. Bourguinat - Palais universitaire - 67084 Strasbourg Cedex - tél. 03 68 85 68 08 courriel : [email protected] Impression : Service imprimerie et reprographie de l’Université de Strasbourg ISSN de la version imprimée : 2265-1306 ISSN du présent support électronique : 2261-8592 SOMMAIRE I. DOSSIER : L’INDIVIDU DANS LES CONFLITS 7 Présentation Jean-Pascal Gay 11 « Que faisais-tu sous l’oligarchie ? » La guerre civile de 404-403 et ses lendemains à Athènes Anne Jacquemin 23 Pierre II de Challes, capitaine armagnac (1409-1436). Renseignement, désinformation et pillage durant la guerre civile Benoît Léthenet 37 Face à l’occupation étrangère de 1815-1818. Les sorties de guerre des Alsaciens Christine Haynes 51 « Un métier de chien que de suivre l’armée ». Prosper Baccuët (1797-1864), peintre militaire au service de l’exploration scientifique de l’Algérie Nicolas Schaub 65 Quand un neutre prend les armes.